Latest Nektar Therapeutics News & Updates

See the latest news and media coverage for Nektar. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Nektar Therapeutics (Nektar)

Biopharmaceutical company developing autoimmune and inflammatory therapies

nektar.com
Headquarters
San Francisco, United States
Founded year
1990
Company type
Public company
Number of employees
50–700
Industry
Pharmaceuticals

Last updated

Latest news about Nektar Therapeutics (Nektar)

In short: Nektar advanced its rezpegaldesleukin pipeline into Phase 3 trials and reached a cash position of over $1 billion by mid-2026.

Company announcements

Nektar

Nektar announces Q2 2026 financial results

Cash and investments total $1,023.4 million, up from $245.8 million at end of 2025. Net loss narrowed to $40.6 million, and cash runway extends to Q3 2028.

Nektar

Nektar initiates Phase 3 ZENITH AD program for atopic dermatitis

The program includes three global trials evaluating rezpegaldesleukin in moderate-to-severe atopic dermatitis, with initial data expected in mid-2028 and BLA submission targeted for 2029.

Unlock all announcements with a

Media coverage

Law360

Nektar Therapeutics v. Eli Lilly & Co

Nektar Therapeutics' damages expert told a California federal jury on Thursday that Eli Lilly & Co. could owe the biotechnology company nearly $1 billion if...

The Market is Open

Nektar Therapeutics Hits a High Note in Q2 2026: REZPEG Advances to Phase III, Market Opportunity Shines

Nektar Therapeutics, a biopharmaceutical company focused on developing innovative therapies for patients with serious and complex diseases, has announced another significant milestone in its Q2...

Unlock all articles with a

Never miss news about Nektar

Track Nektar and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Nektar competitors & trending companies

Browse news for competitors to Nektar and other trending companies.